|
May 16
|
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer
|
|
May 9
|
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
|
|
May 7
|
The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028
|
|
May 6
|
Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
|
Apr 30
|
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series
|
|
Mar 23
|
Regulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancements
|
|
Mar 21
|
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
|
|
Mar 14
|
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
|
|
Mar 13
|
Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study
|
|
Mar 12
|
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
|
|
Mar 12
|
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
|
Aug 8
|
Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates
|